| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/23/2005 | CN1585645A Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
| 02/23/2005 | CN1585640A N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 02/23/2005 | CN1585636A Use of endothelin receptor antagonists in the treatment of tumour diseases |
| 02/23/2005 | CN1585634A Pharmaceutical composition comprising an adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor |
| 02/23/2005 | CN1585633A Phenethanolamine derivatives for treatment of respiratory diseases |
| 02/23/2005 | CN1583753A Dioxazole pyrimidine nucleotide compounds with function of releasing NO and its use in pharmaceutics |
| 02/23/2005 | CN1583164A Preparing procedure of transfer factor for intravenous injection |
| 02/23/2005 | CN1583143A Horn removing ointment for cow |
| 02/23/2005 | CN1583044A External used Chinese medicinal composition for abdominal external hernia |
| 02/23/2005 | CN1582979A Brain and intellectual health care medicine and its preparation |
| 02/23/2005 | CN1582964A Sheep fetus health care products and their products |
| 02/23/2005 | CN1582905A Use of emodin in preparation of antagonistic TGF beta-1 and medicines to prevent tissues from fibrosis |
| 02/23/2005 | CN1190491C PRV-gene and use thereof |
| 02/23/2005 | CN1190445C Process for producing functional silk fibroin and utilization of the same |
| 02/23/2005 | CN1190437C Pteridine compounds for treatment of psoriasis |
| 02/23/2005 | CN1190433C Phenylpiperazine |
| 02/23/2005 | CN1190432C Piperazing derivatives as 5-HTIB antagonists |
| 02/23/2005 | CN1190424C Quinoline-containing Alpha-ketoamide cysteine and serine protease inhibitors |
| 02/23/2005 | CN1190417C Prostaglandin Derivatives |
| 02/23/2005 | CN1190394C Pineapplie leaf extract and its preparation method and application |
| 02/23/2005 | CN1190235C Process for preparing health-care compound sheep placenta extract food series |
| 02/23/2005 | CN1190234C Technology for industrially preparing spirulina polynutrient |
| 02/23/2005 | CN1190200C Compsns. comprising mixture of bioflavonols |
| 02/23/2005 | CN1190192C Capsule agent with grape-seed extracts as raw material |
| 02/22/2005 | US6858750 Such as Parkinson's syndrome, Alzheimer's disease, Huntington's disease, retinopathia pigmentosa and mitochondrial encephalomyopathy; preferred are dialkyl fumarate, monoalkyl fumarate and is salts |
| 02/22/2005 | US6858739 Indole and benzimidazole 15-lipoxygenase inhibitors |
| 02/22/2005 | US6858722 Oligomer phosphoramidite compositions and processes for synthesizing the same |
| 02/22/2005 | US6858716 Drosophila recombination-associated protein and methods for use |
| 02/22/2005 | US6858649 Contacting the cell having the human serotonin receptor subtype 5-HT1A with a quantity of a serotonergic agent possessing 5- HT1A agonist activity sufficient for potentiating the serotonin response within cell |
| 02/22/2005 | US6858645 Prevention or the treatment of CNS disorders and related medical disturbances comprising effective amount of the salt according dissolving (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5 -carboxamide in an appropriate |
| 02/22/2005 | US6858643 Crystalline forms of Fluvastatin sodium |
| 02/22/2005 | US6858641 Substituted indolinones |
| 02/22/2005 | US6858640 Tricyclic indole compounds having affinity for serotonin receptor |
| 02/22/2005 | US6858638 Substituted indazoles, compositions containing them, method of production and use |
| 02/22/2005 | US6858629 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 02/22/2005 | US6858628 Substituted cyclic amine metalloprotease inhibitors |
| 02/22/2005 | US6858626 Cyclic hydroxamic acid as metalloproteinase inhibitors |
| 02/22/2005 | US6858624 Comprises 5,8,14-triazatetracyclo(10.3.1.0.0)-hexadeca-2(11),3,5,7,9-penaene groups; for reducing drug addiction, treating Alzheimer's/Parkinson's diseases, and other nervous system disorders |
| 02/22/2005 | US6858620 For therapy of male erectile dysfunction; female arousal disorder |
| 02/22/2005 | US6858619 Fused heterocyclic compounds |
| 02/22/2005 | US6858615 Phenyl guanidine sodium channel blockers |
| 02/22/2005 | US6858612 Use of tetrahydropteridine derivatives as no synthase inhibitors |
| 02/22/2005 | US6858610 Autoimmune disease; antiinflammatory agents |
| 02/22/2005 | US6858594 Compounds and methods for treating urinary incontinence |
| 02/22/2005 | US6858580 Immobilization of drugs |
| 02/22/2005 | US6858578 Chimeric proteins for use in transport of a selected substance into cells |
| 02/22/2005 | US6858431 An osteoinductive soluble factor induced by the expression of human mineralization protein. |
| 02/22/2005 | US6858420 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/22/2005 | US6858411 Recombinant nucleic acids that encode epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells to produce epothilone derivatives/polyketides; used as cancer drugs, fungicides and immunosuppressants |
| 02/22/2005 | US6858407 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 02/22/2005 | US6858206 Methods for treating diseases caused by deficiencies of recombinant alpha-L-iduronidase |
| 02/22/2005 | CA2271232C Modified protein c and methods of use thereof |
| 02/22/2005 | CA2218493C Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| 02/22/2005 | CA2185352C Novel muteins of ifn-.beta. |
| 02/17/2005 | WO2005014657A1 Method of processing seaweed |
| 02/17/2005 | WO2005014584A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 02/17/2005 | WO2005014576A1 Isoquinolinone derivative, process for producing the same and use thereof |
| 02/17/2005 | WO2005014561A1 Compounds having thrombopoietin receptor agonism |
| 02/17/2005 | WO2005013991A1 Dry syrup containing loratadine |
| 02/17/2005 | WO2005013966A1 Macrophage activation inhibitor |
| 02/17/2005 | WO2004091592A3 Methods and compositions to treat myocardial conditions |
| 02/17/2005 | WO2004002999A8 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 02/17/2005 | WO2003106449A8 Novel aryl-{4-halo-4-[heteroarylmethylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments |
| 02/17/2005 | WO2002083714A3 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050039232 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses |
| 02/17/2005 | US20050038259 Elastase release inhibitors; such as 19-(1H-tetrazol-5-yl)nonadec-6-en-5-ol |
| 02/17/2005 | US20050038249 metal complexes used as prodrugs that may be activated under hypoxic conditions by enzymes or by radiotherapy for treatment of cancer |
| 02/17/2005 | US20050038243 2, 4-pyrimidinediamine compounds and their uses |
| 02/17/2005 | US20050038242 Pyrrolothiazine and pyrrolothiazephine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 02/17/2005 | US20050038119 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion |
| 02/17/2005 | US20050038113 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
| 02/17/2005 | US20050038108 4S, 5R, 6R)-5-Acetylamino-4-azido-6-[(S)-4-nitrophenoxycarbonyloxy)-(2-oxo-[1,3]dioxolan-4R-yl)methyl]- 5,6-dihydro-4H-pyran2-carboxylic acid methylester; modified at the carboxyl or hydroxyl or amino functions; orthomyxovirus and paramyxovirus infections; a long lung residency time and high potency |
| 02/17/2005 | US20050038095 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 02/17/2005 | US20050038084 Phenylalanine enamide derivatives |
| 02/17/2005 | US20050038072 Nitrogeneous cyclic ketone derivative, process for producing the same, and use |
| 02/17/2005 | US20050038069 Tumor necrosis factor antagonist; antiinflammatory agents; such as 2-Cyclopropyl-4-(3,5-dimethyl-4-pyridylmethoxy)-7-methoxy-3H-benzimidazole |
| 02/17/2005 | US20050038060 Spiropoperidine compounds as ligands for orl-1 receptor |
| 02/17/2005 | US20050038045 A2B adenosine receptor antagonists |
| 02/17/2005 | US20050038044 For drug resistance disease; side effect reduction; antiinflammatory agents; autoimmune disease |
| 02/17/2005 | US20050038037 N-(naphth-2-ylaminocarbonylacetyl)- or N-(naphth-2-ylcarbonylamino- acetyl)- piperazine derivatives, e.g., 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]aminonaphthalene; useful as antithrombotic agents |
| 02/17/2005 | US20050038029 Transferring, releasing nitric oxide; side effect reduction; using a compound containing nitrosos group |
| 02/17/2005 | US20050038028 Hydroxyethylene compounds with asp2 inhibitory activity |
| 02/17/2005 | US20050038027 Melanocortin-4 receptor agonists; obesity, type II diabetes; such as N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-(2,6,6-trimethylbicyclo(3.1.1)hept-3yl)piperazine-1-carboximidamide |
| 02/17/2005 | US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 02/17/2005 | US20050038022 Using a benzimidazole carbamate compound in lipid carrier; antitumor agents |
| 02/17/2005 | US20050038019 Hydroxy substituted amides for the treatment of alzheimer's disease |
| 02/17/2005 | US20050038015 Partial dopamine-D 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity |
| 02/17/2005 | US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 02/17/2005 | US20050038009 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- alpha -[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine |
| 02/17/2005 | US20050038008 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 02/17/2005 | US20050038002 Bactericides; antitumor agents; moderators of gene expression; viricides; parasiticides; malaria therapy |
| 02/17/2005 | US20050037993 Bulking agents as satiety agents |
| 02/17/2005 | US20050037990 Disubstituted 7,9-guanines halides as telomerase inhibitors |
| 02/17/2005 | US20050037984 Administering protein kinase C activator |
| 02/17/2005 | US20050037976 Hematopoietic stimulation |
| 02/17/2005 | US20050037971 Use of hepcidin as a regulator of iron homeostasis |
| 02/17/2005 | US20050037968 Peptide leukotriene receptor |
| 02/17/2005 | US20050037956 Screening method for agents useful in treating diabetes |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |